Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01471210 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 study of Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT01471210 is a Phase 1 study of Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 124 participants. The trial reports 20 study locations across 11 states.
The verdict
NCT01471210, a Phase 1 study of Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma
Conditions Studied
Interventions
- DRUG Urelumab (BMS-663513)
Study Locations (20)
Other
- Local Institution - Créteil
- Local Institution - Lille
- Local Institution - Paris
- Local Institution - Pessac
- Local Institution - Pierre-Bénite
- Local Institution - Rennes
- Local Institution - Rouen
- Local Institution - Villejuif
California
- Division Of Hematology & Oncology Ctr. For Health Sciences - Los Angeles
- Stanford University Medical Center - Stanford
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
- Hospital Of The University Of Pennsylvania - Philadelphia
Illinois
- University Of Chicago - Chicago
Indiana
- Indiana University Cancer Center - Indianapolis
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- John Theurer Cancer Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01471210
The ClinicalTrials.gov registry entry for NCT01471210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Urelumab (BMS-663513) is the first listed.
NCT01471210 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01471210 about?
NCT01471210 is a clinical study titled "Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma". The purpose of the study is to assess the safety, tolerability, pharmacokinetics and immunoregulatory activity of urelumab (BMS-663513) in cancer subjects with advanced and/or metastatic tumors and relapsed/refractory B-Cell Non-Hodgkin's Lymphoma
What is the current status of trial NCT01471210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2012-02. Estimated completion is 2016-04.
What conditions does trial NCT01471210 study?
This clinical trial studies the following conditions: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01471210?
The interventions under investigation include: Urelumab (BMS-663513) (DRUG).
Who is sponsoring clinical trial NCT01471210?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01471210 being conducted?
This trial has 20 study locations across California, Illinois, Indiana, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.